New hope for rare blood clotting disorder? daratumumab under study
NCT ID NCT07513948
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is collecting information from 40 patients with a rare blood disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP) who have been treated with daratumumab. The goal is to see how well daratumumab works and how safe it is for patients whose disease did not respond to standard treatments. Researchers will measure response by looking at ADAMTS13 enzyme activity levels and track any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- daratumumab
- What this could lead to
- If this study shows daratumumab is effective, it could point toward a new treatment option for people with iTTP who do not respond to standard therapies.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less conclusive. The number of participants is small (40), and daratumumab may cause side effects like infections or infusion reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
RECRUITINGMilan, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.